Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing

Reuters

2025/06/05

Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing

Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-081674), on June 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541432099"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541432099\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2541432099?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 04:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541432099","market":"nz","top_or_hot":-1,"title":"Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-081674), on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 04:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-081674), on June 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250604:nNDL9d0W9y:1","article_id":"2541432099","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541432099","pubTimestamp":1749069503,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus Inc.和Zydus签署1.41亿美元协议，以促进BOT/BAL并扩大美国生物制剂生产","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. and Zydus Ink $141M Deal to Boost BOT/BAL and Expand US Biologics Manufacturing\n    \n\n        Agenus Inc. has announced a strategic collaboration with Zydus Lifesciences, valued at $141 million, to advance the development of BOT/BAL and expand Zydus' biologics manufacturing capabilities in the United States. The agreement includes a $75 million upfront payment to Agenus for the transfer of its biologics CMC facilities in Emeryville and Berkeley, California. Agenus is set to receive up to an additional $50 million in contingent payments based on production orders. As part of the deal, Agenus will become Zydus' first BioCDMO customer through an exclusive manufacturing agreement for BOT/BAL, aimed at ensuring BLA and launch readiness. Additionally, Zydus will gain an exclusive license for BOT/BAL in India and Sri Lanka, along with a $16 million equity investment in Agenus. This collaboration reflects a strengthened partnership between the U.S. and India in biopharma and aims to secure strategic capital for global regulatory engagement and commercialization.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-081674), on June 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}